Is OptimizeRx Corp. overvalued or undervalued?

As of 4 May 2022, OptimizeRx Corp. moved from a fair to a risky valuation grade. The company appears to be overvalued, given its significant negative valuation ratios, including an EV to EBIT of -86.78 and a P/E ratio that is not applicable due to losses. Additionally, its Price to Book Value stands at 2.33, indicating a premium over its book value, which is concerning in the context of its financial performance.
In comparison to peers, OptimizeRx Corp. has a notably high EV to EBITDA ratio of 271.52, while Blacksky Technology, Inc. has a much lower EV to EBITDA of -67.11, and ReposiTrak, Inc. shows a fair valuation with a P/E of 47.10. The company's recent stock performance has been impressive, with a year-to-date return of 289.30%, significantly outperforming the S&P 500's 12.22% return, but this does not mitigate the underlying valuation concerns.